POST-TEST Hematologic Oncology Update — issue 1, 2014 The c o rrec T answer is indicaTed wiTh yellow highlighTin g. 1. Which of the following is true regarding the 6. A Phase II study of single-agent brentux- CRS related to CAR T-cell therapy? imab vedotin for the treatment of relapsed a. It manifests as fever, nausea, myalgia or refractory CD30-positive non-hodgkin and hypotension lymphomas demonstrated promising antitumor b. It is associated with high levels of IL-6 activity in patients with DLBCL with a broad c. It is irreversible range of CD30 expression levels. d. Both a and b a. True b. False 2. Updated results of a pilot trial by Porter and colleagues of chimeric antigen receptor T-cell 7. Results from a Phase II trial comparing therapy for patients with relapsed/refractory consolidation therapy with a single dose of CLL reported an overall response rate of 90y-ibritumomab tiuxetan to rituximab mainte- _____________. nance for patients with newly diagnosed Fl a. 12% who have experienced a response to r-CHOP b. 57% demonstrated statistically significant differ- ences in _____________ favoring rituximab c. 82% maintenance. 3. Tocilizumab, an IL-6 receptor antagonist, is a. Progression-free survival effective at reversing the cytokine release b. Overall survival syndrome associated with chimeric antigen c. Both a and b receptor-modified T-cell therapy. a. True 8. The final stage II results of the Phase b. False III CLL11 trial for patients with CLL and coexisting medical conditions demon- 4. The results of a Phase III study of induction strated that obinutuzumab/chlorambucil was therapy with lenalidomide and dexametha- superior to rituximab/chlorambucil in terms of sone followed by maintenance lenalidomide _____________. for patients with high-risk sMM demonstrated a. Progression-free survival a statistically significant improvement in b. Overall response rate _____________ versus observation only. c. Both a and b a. Time to disease progression b. Three-year OS rate 9. Based on the results of a study by yilmaz c. Five-year OS rate and colleagues, long-term treatment with _____________ may result in a significant d. All of the above decline in the glomerular filtration rate in 5. The ongoing Phase III ECOG-e3a06 trial is patients with cMl. evaluating _____________ versus observation a. Dasatinib alone for patients with asymptomatic high-risk b. Imatinib sMM. c. Nilotinib a. Lenalidomide b. Lenalidomide in combination with 10. _____________ is an FDA-approved potent TKi low-dose dexamethasone for the treatment of chronic myeloid leukemia that was temporarily suspended because of a c. Lenalidomide in combination with high- risk of serious thrombosis and stenosis. dose dexamethasone a. Ponatinib b. Bosutinib c. Dasatinib d. Omacetaxine mepesuccinate e. All of the above.